Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Forum Dermatologicum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 9, No 2 (2023)
Review paper
Published online: 2023-04-05
Add to basket: 49.00 PLN
Get Citation

Factors affecting the clinical picture of atopic dermatitis

Joanna Krzysiek1, Aleksandra Lesiak1, Joanna Narbutt1
DOI: 10.5603/FD.a2023.0008
·
Forum Dermatologicum 2023;9(2):61-70.
Affiliations
  1. Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Poland

paid access

Vol 9, No 2 (2023)
REVIEW ARTICLES
Published online: 2023-04-05

Abstract

Atopic dermatitis (AD) is a chronic and recurrent disease affecting both, children and adults. Over the last decades, its prevalence has been constantly growing, causing significant psychological and social issues. Risk factors have been associated with the development of AD such as genetic, environmental, and abnormal immune response, as well as disorders of the skin barrier and skin microbiome. The following review comprehensively discusses all aspects affecting the clinical picture of AD. It allows a better understanding of the mechanisms underlying disease and may initiate appropriate treatment.

Abstract

Atopic dermatitis (AD) is a chronic and recurrent disease affecting both, children and adults. Over the last decades, its prevalence has been constantly growing, causing significant psychological and social issues. Risk factors have been associated with the development of AD such as genetic, environmental, and abnormal immune response, as well as disorders of the skin barrier and skin microbiome. The following review comprehensively discusses all aspects affecting the clinical picture of AD. It allows a better understanding of the mechanisms underlying disease and may initiate appropriate treatment.

Full Text:

Add to basket: 49.00 PLN
Get Citation

Keywords

atopic dermatitis, etiopathogenesis, risk factors

About this article
Title

Factors affecting the clinical picture of atopic dermatitis

Journal

Forum Dermatologicum

Issue

Vol 9, No 2 (2023)

Article type

Review paper

Pages

61-70

Published online

2023-04-05

Page views

2221

Article views/downloads

32

DOI

10.5603/FD.a2023.0008

Bibliographic record

Forum Dermatologicum 2023;9(2):61-70.

Keywords

atopic dermatitis
etiopathogenesis
risk factors

Authors

Joanna Krzysiek
Aleksandra Lesiak
Joanna Narbutt

References (102)
  1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015; 66 Suppl 1: 8–16.
    CrossRefPubMed
  2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70(2): 338–351.
    CrossRefPubMed
  3. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups — Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018; 27(4): 340–357.
    CrossRefPubMed
  4. Blume-Peytavi U, Metz M. Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 6: 2–8.
    CrossRefPubMed
  5. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3): 340–347.
    CrossRefPubMed
  6. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018; 120(2): 131–137.
    CrossRefPubMed
  7. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019; 123(2): 144–151.
    CrossRefPubMed
  8. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol. 1995; 75(6): 429–433.
    CrossRefPubMed
  9. Lesiak A, Zakrzewski M, Przybyłowska K, et al. Combined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitis. Exp Dermatol. 2011; 20(6): 491–495.
    CrossRefPubMed
  10. Palmer C, Irvine A, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genetics. 2006; 38(4): 441–446.
    CrossRef
  11. Gimalova GF, Karunas AS, Fedorova YY, et al. The study of filaggrin gene mutations and copy number variation in atopic dermatitis patients from Volga-Ural region of Russia. Gene. 2016; 591(1): 85–89.
    CrossRefPubMed
  12. Margolis DJ, Mitra N, Gochnauer H, et al. Uncommon filaggrin variants are associated with persistent atopic dermatitis in African Americans. J Invest Dermatol. 2018; 138(7): 1501–1506.
    CrossRefPubMed
  13. Margolis DJ, Mitra N, Wubbenhorst B, et al. Association of filaggrin loss-of-function variants with race in children with atopic dermatitis. JAMA Dermatol. 2019; 155(11): 1269–1276.
    CrossRef
  14. Margolis DJ, Gupta J, Apter AJ, et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J Allergy Clin Immunol. 2014; 133(3): 784–789.
    CrossRefPubMed
  15. Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int. 2018; 67(1): 3–11.
    CrossRefPubMed
  16. Brattsand M, Stefansson K, Lundh C, et al. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol. 2005; 124(1): 198–203.
    CrossRefPubMed
  17. Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016; 42: 1–8.
    CrossRefPubMed
  18. Jungersted JM, Scheer H, Mempel M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010; 65(7): 911–918.
    CrossRef
  19. van Smeden J, Janssens M, Kaye ECJ, et al. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol. 2014; 23(1): 45–52.
    CrossRefPubMed
  20. Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 2004; 17 Suppl 1: 43–48.
    CrossRefPubMed
  21. Oyoshi MK, Murphy GF, Geha RS. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol. 2009; 124(3): 485–493.e1.
    CrossRefPubMed
  22. Niedoszytko B. Czy atopowe zapalenie skóry jest chorobą dziedziczną? In: Nowicki R. ed. ABC atopowego zapalenia skóry. AZS w pytaniach i odpowiedziach. Termedia Wydawnictwa Medyczne, Poznań 2015: 11–21.
  23. Bin L, Leung DYM. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol. 2016; 12: 52.
    CrossRefPubMed
  24. Mu Z, Zhang J. The role of genetics, the environment, and epigenetics in atopic dermatitis. Adv Exp Med Biol. 2020; 1253: 107–140.
    CrossRefPubMed
  25. Hidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017; 18(1): 64–73.
    CrossRefPubMed
  26. Kim K, et al. Influences of environmental chemicals on atopic dermatitis. Toxicol Res. 2015; 31(2): 89–96.
    CrossRefPubMed
  27. Montnemery P, Nihlén U, Göran Löfdahl C, et al. Prevalence of self-reported eczema in relation to living environment, socio-economic status and respiratory symptoms assessed in a questionnaire study. BMC Dermatol. 2003; 3: 4.
    CrossRefPubMed
  28. Kim J, Han Y, Ahn JH, et al. Airborne formaldehyde causes skin barrier dysfunction in atopic dermatitis. Br J Dermatol. 2016; 175(2): 357–363.
    CrossRefPubMed
  29. Lee H, Shin JJ, Bae HC, et al. Toluene downregulates filaggrin expression via the extracellular signal-regulated kinase and signal transducer and activator of transcription-dependent pathways. J Allergy Clin Immunol. 2017; 139(1): 355–358.e5.
    CrossRefPubMed
  30. Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol. 2013; 133(7): 1752–1759.
    CrossRefPubMed
  31. Engebretsen KA, Bager P, Wohlfahrt J, et al. Prevalence of atopic dermatitis in infants by domestic water hardness and season of birth: Cohort study. J Allergy Clin Immunol. 2017; 139(5): 1568–1574.e1.
    CrossRefPubMed
  32. Gfatter R, Hackl P, Braun F. Effects of soap and detergents on skin surface pH, stratum corneum hydration and fat content in infants. Dermatology. 1997; 195(3): 258–262.
    CrossRefPubMed
  33. Törmä H, Lindberg M, Berne B. Skin barrier disruption by sodium lauryl sulfate-exposure alters the expressions of involucrin, transglutaminase 1, profilaggrin, and kallikreins during the repair phase in human skin in vivo. J Invest Dermatol. 2008; 128(5): 1212–1219.
    CrossRefPubMed
  34. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003; 23(15): 6176–6180.
    CrossRefPubMed
  35. Wang IJ, Chen SL, Lu TP, et al. Prenatal smoke exposure, DNA methylation, and childhood atopic dermatitis. Clin Exp Allergy. 2013; 43(5): 535–543.
    CrossRefPubMed
  36. Yoshihisa Y, Shimizu T. Metal allergy and systemic contact dermatitis: an overview. Dermatol Res Pract. 2012: 749561.
    CrossRefPubMed
  37. Thyssen JP, McFadden JP, Kimber I. The multiple factors affecting the association between atopic dermatitis and contact sensitization. Allergy. 2014; 69(1): 28–36.
    CrossRefPubMed
  38. Yim E, Baquerizo Nole KL, Tosti A. Contact dermatitis caused by preservatives. Dermatitis. 2014; 25(5): 215–231.
    CrossRefPubMed
  39. Nowicki R, Trzeciak M, Kaczmarski M, et al. Atopowe zapalenie skóry. Interdyscyplinarne rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Alergologicznego, Polskiego Towarzystwa Pediatrycznego oraz Polskiego Towarzystwa Medycyny Rodzinnej. Część I. Profilaktyka, leczenie miejscowe i fototerapia. Dermatol Rev/Przegl Dermatol. 219; 106(4): 354–374.
    CrossRef
  40. Björkstén B. Genetic and environmental risk factors for the development of food allergy. Curr Opin Allergy Clin Immunol. 2005; 5(3): 249–253.
    CrossRefPubMed
  41. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012; 22(5): 850–859.
    CrossRefPubMed
  42. Leung DYM. Infection in atopic dermatitis. Curr Opin Pediatr. 2003; 15(4): 399–404.
    CrossRefPubMed
  43. Williams MR, Gallo RL. Evidence that human skin microbiome dysbiosis promotes atopic dermatitis. J Invest Dermatol. 2017; 137(12): 2460–2461.
    CrossRefPubMed
  44. Spaulding AR, Salgado-Pabón W, Kohler PL, et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013; 26(3): 422–447.
    CrossRefPubMed
  45. Cheung GYC, Joo HS, Chatterjee SS, et al. Phenol-soluble modulins - critical determinants of staphylococcal virulence. FEMS Microbiol Rev. 2014; 38(4): 698–719.
    CrossRefPubMed
  46. Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol. 2014; 17: 32–37.
    CrossRefPubMed
  47. Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature. 2013; 503(7476): 397–401.
    CrossRefPubMed
  48. Nakatsuji T, Chen TH, Two AM, et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J Invest Dermatol. 2016; 136(11): 2192–2200.
    CrossRefPubMed
  49. Simpson EL, Villarreal M, Jepson B, et al. Patients with atopic dermatitis colonized with staphylococcus aureus have a distinct phenotype and endotype. J Invest Dermatol. 2018; 138(10): 2224–2233.
    CrossRefPubMed
  50. Kaesler S, Volz T, Skabytska Y, et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J Allergy Clin Immunol. 2014; 134(1): 92–99.
    CrossRefPubMed
  51. Mrabet-Dahbi S, Dalpke AH, Niebuhr M, et al. The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol. 2008; 121(4): 1013–1019.
    CrossRefPubMed
  52. Oh DY, Schumann RR, Hamann L, et al. Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis. Allergy. 2009; 64(11): 1608–1615.
    CrossRefPubMed
  53. Allakhverdi Z, Smith DE, Comeau MR, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007; 204(2): 253–258.
    CrossRefPubMed
  54. Al Kindi A, Williams H, Matsuda K, et al. Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33. J Allergy Clin Immunol. 2021; 147(4): 1354–1368.e3.
    CrossRefPubMed
  55. Teufelberger AR, Nordengrün M, Braun H, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol. 2018; 141(2): 549–559.e7.
    CrossRefPubMed
  56. Al Kindi A, Williams H, Matsuda K, et al. Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33. J Allergy Clin Immunol. 2021; 147(4): 1354–1368.e3.
    CrossRefPubMed
  57. Liu H, Archer NK, Dillen CA, et al. Staphylococcus aureus epicutaneous exposure drives skin inflammation via il-36-mediated t cell responses. Cell Host Microbe. 2017; 22(5): 653–666.e5.
    CrossRefPubMed
  58. Nakagawa S, Matsumoto M, Katayama Y, et al. Staphylococcus aureus virulent psmα peptides induce keratinocyte alarmin release to orchestrate il-17-dependent skin inflammation. Cell Host Microbe. 2017; 22(5): 667–677.e5.
    CrossRefPubMed
  59. Yu J, Oh MH, Park JU, et al. Epicutaneous exposure to staphylococcal superantigen enterotoxin B enhances allergic lung inflammation via an IL-17A dependent mechanism. PLoS One. 2012; 7(7): e39032.
    CrossRefPubMed
  60. Tsilochristou O, Toit Gdu, Sayre P, et al. Association of Staphylococcus aureus colonization with food allergy occurs independently of eczema severity. J Allergy Clinical Immunol. 2019; 144(2): 494–503.
    CrossRef
  61. Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016; 137(4): 1071–1078.
    CrossRefPubMed
  62. Jones AL, Curran-Everett D, Leung DYM. Food allergy is associated with Staphylococcus aureus colonization in children with atopic dermatitis. J Allergy Clin Immunol. 2016; 137(4): 1247–1248.e3.
    CrossRefPubMed
  63. Hrestak D, Matijašić M, Čipčić Paljetak H, et al. Skin microbiota in atopic dermatitis. Int J Mol Sci. 2022; 23(7).
    CrossRefPubMed
  64. Guttman-Yassky E, Waldman A, Ahluwalia J, et al. Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. 2017; 36(3): 100–103.
    CrossRefPubMed
  65. Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017; 66(3): 398–403.
    CrossRefPubMed
  66. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012; 130(6): 1344–1354.
    CrossRefPubMed
  67. Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013; 131(2): 300–313.
    CrossRefPubMed
  68. Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019; 180(3): 464–474.
    CrossRefPubMed
  69. Furue M, Furue M, et al. OX40L-OX40 signaling in atopic dermatitis. J Clin Med. 2021; 10(12): 2578.
    CrossRefPubMed
  70. Gawrysiak M, et al. Rola komórek ILC2 w rozwoju zapalenia alergicznego. Alergia Astma Immunologia. 2020; 25: 64–69.
  71. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019; 40(2): 84–92.
    CrossRefPubMed
  72. Shang H, Cao XL, Wan YJ, et al. IL-4 gene polymorphism may contribute to an increased risk of atopic dermatitis in children. Dis Markers. 2016: 1021942.
    CrossRefPubMed
  73. Lesiak A, Kuna P, Zakrzewski M, et al. Combined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitis. Exp Dermatol. 2011; 20(6): 491–495.
    CrossRefPubMed
  74. Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020; 75(7): 1582–1605.
    CrossRefPubMed
  75. Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014; 14(5): 433.
    CrossRefPubMed
  76. Bodoor K, Al-Qarqaz F, Heis LAl, et al. IL-33/13 axis and IL-4/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis. Clin Cosmet Investig Dermatol. 2020; 13: 419–424.
    CrossRefPubMed
  77. Rabenhorst A, Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep. 2014; 14(4): 423.
    CrossRefPubMed
  78. Wong CK, Leung KML, Qiu HN, et al. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One. 2012; 7(1): e29815.
    CrossRefPubMed
  79. Yagi Y, Andoh A, Nishida A, et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med. 2007; 19(6): 941–946.
    PubMed
  80. Kimura M, Tsuruta S, Yoshida T. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. J Allergy Clin Immunol. 1998; 45(10): 84–89.
    CrossRefPubMed
  81. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005; 60(5): 693–696.
    CrossRefPubMed
  82. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. 2014; 2(4): 371–380.
    CrossRefPubMed
  83. Oliva M, Renert-Yuval Y, Guttman-Yassky E. The 'omics' revolution: redefining the understanding and treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol. 2016; 16(5): 469–476.
    CrossRefPubMed
  84. Ma L, Xue HB, Guan XH, et al. Possible role of Th17 cells and IL-17 in the pathogenesis of atopic dermatitis in northern China. J Dermatol Sci. 2012; 68(1): 66–68.
    CrossRefPubMed
  85. Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008; 128(11): 2625–2630.
    CrossRefPubMed
  86. Nakajima S, Kitoh A, Egawa G, et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol. 2014; 134(8): 2122–2130.
    CrossRefPubMed
  87. Hayashida S, Uchi H, Moroi Y, et al. Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. J Dermatol Sci. 2011; 61(3): 180–186.
    CrossRefPubMed
  88. Dhingra N, Suárez-Fariñas M, Fuentes-Duculan J, et al. Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. J Allergy Clin Immunol. 2013; 132(2): 498–501.e3.
    CrossRefPubMed
  89. Niebuhr M, Gathmann M, Scharonow H, et al. Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans. Infect Immun. 2011; 79(4): 1615–1622.
    CrossRefPubMed
  90. Maalmi H, Beraies A, Charad R, et al. IL-17A and IL-17F genes variants and susceptibility to childhood asthma in Tunisia. J Asthma. 2014; 51(4): 348–354.
    CrossRefPubMed
  91. Zhai C, Li S, Feng W, et al. Association of interleukin-17a rs2275913 gene polymorphism and asthma risk: a meta-analysis. Arch Med Sci. 2018; 14(6): 1204–1211.
    CrossRefPubMed
  92. Klonowska J, Gleń J, Nowicki RJ, et al. Combination of FLG mutations and SNPs of IL-17A and IL-19 influence on atopic dermatitis occurrence. Advances Dermatol Allergol. 2022; 39(1): 200–208.
    CrossRefPubMed
  93. Shibata S, Saeki H, Tsunemi Y, et al. IL-17F single nucleotide polymorphism is not associated with psoriasis vulgaris or atopic dermatitis in the Japanese population. J Dermatol Sci. 2009; 53(2): 163–165.
    CrossRefPubMed
  94. Holster A, Teräsjärvi J, Barkoff AM, et al. IL17F rs763780 single nucleotide polymorphism is associated with asthma after bronchiolitis in infancy. Acta Paediatr. 2021; 110(1): 222–227.
    CrossRefPubMed
  95. Vandeghinste N, Klattig J, Jagerschmidt C, et al. Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis. J Invest Dermatol. 2018; 138(7): 1555–1563.
    CrossRefPubMed
  96. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016; 137(5): 1347–1358.
    CrossRefPubMed
  97. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci. 2013; 72(1): 3–8.
    CrossRefPubMed
  98. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007; 120(1): 150–155.
    CrossRefPubMed
  99. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007; 120(1): 150–155.
    CrossRefPubMed
  100. Kim BE, Bin L, Ye YM, et al. IL-25 enhances HSV-1 replication by inhibiting filaggrin expression, and acts synergistically with Th2 cytokines to enhance HSV-1 replication. J Invest Dermatol. 2013; 133(12): 2678–2685.
    CrossRefPubMed
  101. Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021; 126(1): 21–31.
    CrossRefPubMed
  102. Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019; 143(1): 1–11.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl